Home » News » 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester

September 23, 2026

1. 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester; CAS: 917392-54-2 is a Impurities, intermediates , alternative names include Nilotinib Epsilon Impurity G.

2. Product Overview
1. 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester, It is a synthetic intermediate of nilotinib, and at the same time, it is also the main impurity specified in the pharmacopoeia.

3. Basic Product Information
Product Name: 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester
Synonyms: Nilotinib Hydrochloride Monohydrate Impurity G;Nilotinib Hydrochloride Monohydrate EP Impurity G;Methyl 4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)benzoate, Methyl 4-Methyl-3-(4-(pyridin-3-yl)pyriMidin-2-ylaMino)benzoate
CAS: 917392-54-2
MF: C18H16N4O2
MW: 320.35
Structural formula:

Purity: 99%
Melting point: 148 – 150°C
Boiling point: 538.6±60.0 °C(Predicted)
Density: 1.258
Storage temp: 2-8°C
Solubility Chloroform: (Slightly), DMSO (Slightly)
Pka: 2.70±0.12(Predicted)
Appearance: Pale Yellow to Light Beige Solid

HS code: 2934999099
Product Manager Email:crystal@coreychem.com

4. Frequently Asked Questions (FAQ)
*. What is the main purpose of 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid methyl ester ?
Serving as a pharmaceutical impurity reference standard, it is applied in the quality‑related research of Nilotinib (Tasigna, a targeted therapeutic agent for chronic myeloid leukemia); meanwhile, it functions as a pharmaceutical synthetic intermediate for the preparation of nilotinib active pharmaceutical ingredient (API).
*.Product Source and Formation Pathway
CAS 917392-54-2, namely methyl 4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate, is an upstream ester intermediate in the synthetic route of nilotinib. This compound can be converted to the corresponding carboxylic acid via alkaline hydrolysis, and subsequently undergoes amide condensation to produce nilotinib active pharmaceutical ingredient (API).
If the hydrolysis reaction is incomplete, residual methyl ester may remain in the final nilotinib product, forming a process-related impurity, i.e., Nilotinib EP Impurity G listed in the European Pharmacopoeia. This impurity is a related substance that must be strictly controlled in nilotinib API.
Accordingly, this product is mainly used as a nilotinib synthesis intermediate, impurity reference standard and R&D reference material, and shall not be directly used as a finished drug product or active pharmaceutical ingredient
*. Key Physicochemical Properties Requiring Attention During Use
This compound is relatively sensitive to alkaline conditions and prone to ester bond hydrolysis. Sample solutions shall not be stored for prolonged periods in alkaline mobile phases or alkaline media; fresh preparation immediately prior to use is recommended. If the solution is stored overnight after preparation, a carboxylic acid degradation peak may appear, leading to overestimated test results.
The compound also exhibits certain sensitivity to heat and light. The color of solid samples may gradually darken under elevated temperature or prolonged exposure. Therefore, high temperature, strong light and unnecessary exposure should be avoided during storage, weighing and testing.
*. Solubility and Hygroscopicity
This compound is soluble in organic solvents such as DMSO, DMF and dichloromethane, and practically insoluble in water. It should be noted that if the compound comes into contact with an aqueous phase under alkaline conditions, the methyl ester moiety may undergo hydrolysis to form the corresponding carboxylic acid impurity. Therefore, direct dissolution of the solid sample in water is not recommended, and prolonged storage of the solution in an alkaline aqueous environment should be avoided.
*.Practical Operational Precautions
Storage conditions: Store sealed under refrigeration, preferably at 2–8 ℃. After removal from low-temperature storage, allow the container to equilibrate to room temperature before opening to minimize moisture uptake or condensation effects.
Light protection: Use amber bottles or other light-protective containers to avoid light-induced changes.
Solution preparation: Prepare sample solutions fresh for immediate use; avoid prolonged storage under alkaline conditions to prevent hydrolysis and formation of carboxylic acid degradants.
Solvent selection: Prefer suitable organic solvents for dissolution; direct dissolution of the solid in water is prohibited.
Drying control: If drying is required, the temperature shall not exceed 50 ℃ to avoid exposure to elevated temperature.
Weighing protection: Dust-proof measures shall be taken during weighing to avoid inhalation of dust, and appropriate protection for skin, eyes and respiratory tract shall be provided.

5. Application Cases
* Pharmaceutical intermediate/reference substance: It is a pyridine-type pharmaceutical intermediate, primarily used for nilotinib-related R&D, synthetic route studies, analytical method development, and as an impurity reference standard.
* Nilotinib-related impurity/reference standard: Commonly used as Nilotinib EP Impurity G for pharmaceutical quality control, method validation, stability studies, and batch-to-batch consistency assessment.
* Research use: Applicable to coupling reaction studies involving pyrimidine and pyridine structures, heterocyclic compound synthesis, and structural verification in medicinal chemistry projects.
Noted: It is only intended for analytical testing and scientific research and shall not be administered directly to humans.

6. Safety and Storage
Transport Information: Non-hazardous goods
Packing size:
Sample: Sample: brown glass bottle
25kg/Fiber can

Storage temp：
Keep in dark place, Store sealed under refrigeration at 2‑8 °C
Expiration date：
It need to re-test again after 12 month